Analysis of Chronic Inflammation and Haematological Abnormalities

Multiple reports, particularly from 2024 and 2025, show a consistent pattern of a low total white blood cell count (leucopenia) and specifically a low neutrophil count (neutropenia). Report comments have suggested these changes may be related to infection or inflammation.

• White Blood Cell count as low as 3.4 x 10^9/L (Ref: 4.0-10.0) in May 2024.
• Neutrophil count as low as 1.2 x 10^9/L (Ref: 2.0-7.5) in September 2024.
• This chronic suppression of key immune cells represents a significant and persistent health concern.
• Reports from May 2024 and Sept 2024 note mild leucopenia and neutropenia, with comments suggesting infection/inflammation.

The platelet count has been repeatedly flagged as low or borderline-low across several years. While sometimes attributed to lab artifacts like clumping, its recurrence is notable.

• Platelet count recorded at 146 x 10^3/uL (Ref: 150-450) in April 2024.
• Platelet count recorded at 134 x 10^9/L (Ref: 150-410) in May 2024.
• A 2011 report also noted mild thrombocytopenia, suggesting a long-term trend.
• Low platelets can be associated with viral infections, medication, or autoimmune processes.

Rheumatoid Factor (RF) has been consistently elevated since at least 2014, with values significantly above the normal range. This is a strong indicator of an ongoing inflammatory or autoimmune process.

• RF of 38 IU/ml (Ref: <20) in October 2023.
• RF of 39.1 IU/mL (Ref: <14.0) in October 2021.
• RF of 37 IU/ml (Ref: <20) in September 2017.
• RF of 27.6 IU/mL (Ref: <14) in September 2024.
• This long-standing elevation is a key marker of systemic inflammation, even in the context of a negative ANA test.

Homocysteine, an amino acid linked to inflammation and cardiovascular risk, has been consistently measured at high or borderline-high levels.

• Homocysteine recorded at 19.24 umol/L (Ref: 3.70-13.90) in September 2024.
• Homocysteine recorded at 15 umol/L (Ref: 5-15) in September 2017.
• Elevated homocysteine is an independent risk factor for cardiovascular disease and suggests potential issues in the methylation pathway.

While standard cholesterol numbers have fluctuated, a detailed 2024 lipid analysis revealed an unfavorable pattern of small, dense LDL particles (Type B), which are highly atherogenic. This is compounded by a history of elevated LDL and high triglycerides.

• Nutri-STAT profile (Dec 2024) shows LDL Phenotype Pattern 'TYPE B- ABNORMAL' and a low Mean Particle Size of 263.0 Angstrom (Ref > 268.0).
• Triglycerides have been elevated in multiple reports, including 2.40 mmol/L (Ref <1.68) in 2017 and 2.78 mmol/L (Ref <1.70) in 2023.
• Low Apolipoprotein B (0.55 g/L, Ref: 0.63-1.33) and low Apo B/Apo A1 Ratio (0.44) were noted in Sept 2024.
• High-sensitivity C-Reactive Protein (hsCRP) was 2.7 mg/L in 2023, indicating 'Average Risk' for cardiovascular disease.

Markers for glucose metabolism indicate a progression towards Type 2 Diabetes, with a formal pre-diabetic diagnosis in 2021 and evidence of hyperinsulinemia in 2025.

• HbA1c measured at 6.1% in October 2021, within the pre-diabetes range (5.7-6.2%).
• A fasting Insulin level was high at 28.0 uIU/mL (Ref: 3.0-25.0) in June 2025.
• Insulin resistance is a key driver of systemic inflammation and cardiovascular disease.

The estimated Glomerular Filtration Rate (eGFR), a measure of kidney function, has shown a concerning downward trend over the past several years.

• eGFR was consistently >90 in reports from 2013-2021.
• eGFR dropped to 84 in September 2024.
• A Nutri-STAT report in December 2024 showed an eGFR of 72.
• This decline warrants nephrological investigation to prevent further deterioration.

Episodic findings in urine analysis and a calculated liver score point to inflammation and stress in the urinary tract and liver.

• Urine analysis in October 2023 showed significant levels of Leucocytes (33) and Blood (14).
• FIB-4 score for liver fibrosis was 1.79 (Sept 2024) and 1.58 (May 2025), categorized as 'Intermediate risk for advance fibrosis' and warranting follow-up with a Fibroscan.

An Organic Acids Test (OAT) from 2025 revealed markedly elevated levels of oxalate metabolites, which can contribute to systemic inflammation, pain, and crystal formation.

• Glyceric acid was high at 14 mmol/mol creatinine (Ref: 0.21-4.9).
• Oxalic acid was extremely high at 173 mmol/mol creatinine (Ref: 8.9-67).
• High oxalates can be driven by diet, genetic factors, or microbial overgrowth (e.g., Aspergillus, Candida).

Tests have revealed imbalances in key minerals essential for immune function and antioxidant defense, as well as low levels of the adrenal hormone DHEA.

• Serum Zinc and Copper were both found to be low in a September 2024 test.
• The percentage of 'Free Copper' was high at 34% (Ref: 5-25) in December 2024, which can be pro-inflammatory.
• DHEA-Sulphate was low at 1.9 umol/L (Ref: 2.2-15.2) in October 2021, suggesting adrenal stress.